Phase 2 N=2 Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
Multiple Sclerosis
Primary: Incidence of Treatment-Emergent Adverse Events in Subjects by Measuring Measuring Changes in Vital Signs — 0; 0 Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Endometrial Cancer · Endometrial Carcinosarcoma · Endometrial Carcinoma
Primary: Treatment Efficacy Determined by Measuring the Overall Response Rate — 5; 4 Participants
Phase 2 N=16 A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults
Airway Inflammation · Asthma
Primary: Change in Sputum % Polymorphonuclear Neutrophils (PMN) With Wood Smoke Particulate (WSP) Exposure — 18.00; 14.75 percent PMNs — p=0.67
Phase 2 N=222 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Objective Response Rate (ORR) — 17.6; 27.0; 8.8; 8.3 percentage of participants
Phase 2 N=27 Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
Diffuse Cutaneous Systemic Sclerosis
Primary: Number of Participants With at Least One Adverse Event (AE) for IgPro20 — 9; 9 Participants
Phase 2 N=62 Pharmacological Modulation of Hippocampal Activity in Psychosis 2
Schizophrenia; Psychosis
Primary: Hippocampal Activity (Arterial Spin Labeling [ASL] Study) After Levetiracetam (LEV) — 28.3; 27.1; 28.0; 28.5 ml/100g/min
Phase 2 N=44 A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Newly Diagnosed AML With FLT3 Activating Mutations
Primary: Clinical Response to Crenolanib With Standard Induction Chemotherapy — 26; 12; 38; 22 Participants
Phase 2 N=36 Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
Recurrent Kaposi Sarcoma · Skin Kaposi Sarcoma
Primary: Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Positive Participants…
Phase 2 N=75 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Phase 2 N=57 Study in Subjects With Small Primary Choroidal Melanoma
Uveal Melanoma · Ocular Melanoma · Choroidal Melanoma
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] of Light-activated AU-011 — 3; 3; 3; 3 Participants
Phase 2 N=572 A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
Seasonal Influenza
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 37; 63; 59; 60 Participants
Phase 2 N=37 Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Age-Related Macular Degeneration
Primary: Difference in Square-Root Transformed GA Area Expansion Rates in the Study Eye Between the Treatment Phase and Run-in Phase Based on Fundus Autofluorescence (FAF)…
Phase 2 N=80 Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
Venous Thromboembolism · Deep Vein Thrombosis · Pulmonary Embolus
Primary: Number of Participants With Venous Thromboembolism Events — 1 Participants
Phase 2 N=29 Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis
Cystic Fibrosis · Pseudomonas Aeruginosa · Pseudomonas
Primary: Incidence and Severity Treatment Emergent Adverse Events (TEAEs) — 1; 1; 1; 0 Participants
Phase 2 N=87 A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
Adenoid Cystic Carcinoma
Primary: Overall Response Rate (ORR) — 3; 2 Participants